[Malignant Pleural Mesotheliomas]

Area of Science:

• Oncology
• Thoracic Surgery
• Pathology

Background:

• Malignant pleural mesothelioma (MPM) is an aggressive cancer originating from pleural mesothelial cells.
• Asbestos exposure is the primary risk factor, with a long latency period of 30-60 years.
• Clinical presentation is often nonspecific, necessitating accurate pathological diagnosis.

Purpose of the Study:

• To summarize the current understanding of malignant pleural mesothelioma (MPM).
• To highlight diagnostic methods and histological classifications.
• To discuss treatment approaches, emphasizing the shift in surgical philosophies.

Main Methods:

• Diagnosis relies on adequate tissue specimens, with video-assisted thoracoscopic surgery (VATS) offering the highest diagnostic yield.
• Histological classification includes epithelioid, sarcomatoid, and biphasic subtypes.
• Staging involves invasive tests to guide interdisciplinary treatment planning.

Main Results:

• Multi-modal treatment (surgery, radiation oncology, chemotherapy) is superior for eligible patients.
• The primary goal of surgical therapy is macroscopic complete resection.
• A paradigm shift has occurred from extrapleural pneumonectomy (EPP) to radical pleurectomy (RP) as the preferred surgical option.

Conclusions:

• Accurate diagnosis and staging are crucial for optimal multi-modal treatment of MPM.
• Radical pleurectomy (RP) is increasingly favored over extrapleural pneumonectomy (EPP) in surgical management.
• Understanding MPM subtypes and treatment options is vital for patient outcomes.